Project Grant R01AI181383
Award Date
7/10/24
Completion Date
5/31/29
Dollars Obligated
$1.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $1,373,790 grant supports research to develop a next generation of antimalarial compounds called ELQs (endochin-like quinolones) that can provide once-monthly oral protection against malaria. Key objectives include optimizing the structural features of the lead compound ELQ-596 to enhance its anti-plasmodial activity,...
This federal Project Grant award R01AI183599 in the amount of $1,553,810 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to evaluate a genomic surveillance approach for monitoring the emergence of artemisinin resistance in Plasmodium falciparum malaria parasites in Africa. The key objectives are to: 1) identify parasite genetic loci under selection over time...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $690,500 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Trustees of Boston University's Medical Campus to investigate the limited effectiveness of the booster dose of the RTS,S malaria vaccine in African children. The project aims to comprehensively analyze the immune mechanisms underlying the poor antibody responses to the booster dose, including the impacts of repeated malaria...
This $184,109 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to investigate the role of inhibitory immune receptors in regulating monocyte and T cell functions during subclinical malaria infections in children. The research aims to define the immunoregulatory phenotypes of monocytes and T cells, determine monocyte function, and perform transcriptomic analysis to...
The federal Project Grant award R01AI182253, with a total funding amount of $708,202.00, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this 5-year grant is to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The research activities will be conducted by the prime awardee,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $702,204 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the London School of Hygiene and Tropical Medicine (LSHTM) to conduct research on complex malaria in India. The key products and services to be delivered through this 5-year project include: Monitoring the changing epidemiology of malaria in Odisha, India through a 4-year community-based cohort study to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $479,204 to the University of Maryland, Baltimore to conduct research on parasite variant surface antigens and their role in severe malaria. The research aims to identify parasite genes associated with severe disease, which could inform vaccine and drug development. Key aspects include: Sequencing variant surface antigen transcripts...
This federal Project Grant award of $3,762,999.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to advance malaria transmission-blocking vaccine discovery. The research will provide the first comprehensive catalog of surface-exposed proteins in Plasmodium falciparum gametes, zygotes, and ookinetes, with the goal of identifying promising transmission-blocking vaccine (TBV) candidates. Key activities include mass...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $587,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to optimize the structural features of the antimalarial drug candidate ELQ-596 for once-monthly oral prophylaxis in humans. The project aims to develop a next generation of ELQ compounds with improved intrinsic anti-plasmodial activity, enhanced efficacy in animal models, and...
The federal Project Grant award of $459,131, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to identify essential functions of the mitochondrion in malaria parasites. The goal is to uncover novel drug targets within the parasite mitochondrion that could lead to the development of new antimalarial treatments effective against both symptomatic and transmission stages of malaria...